Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy

22 September 2026 Last updated : 22 September 2026 BonTrade
The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.
Categories
BonTrade News
Previous article
Amazon and Shopify make starkly different moves in the brewing battle over AI shoppingNew!!
22 September 2026
Next article
‘She says it’s just money’: My friend pays for everything. I should be grateful, but I can’t stand her anymore.New!!
22 September 2026